NCT06863896

Brief Summary

Several studies have shown laparoscopic technique's advantages, including more rapid post-operative recovery, less post-operative pain, earlier restoration of bowel function, more rapid return to normal diet, and reduced morbidity but it could still remain a complicated operation due to adhesions and difficulty in identifying the rectal stump. Nevertheless, nowadays laparoscopic technique has largely become part of clinical practice even for younger surgeons. Assumed this, and in the lack of prospective studies, we aimed to confirm the advantages of laparoscopic Hartmann reversal (LHR) by confirming the difference in peri-operative outcomes and postoperative complications. In clinical practice, the first question to be asked is whether there is a right timing for a patient to undergo Hartmann's reversal procedure and whether timing influences the incidence of complications (short-terms and long-terms outcomes). Another aim of the study is to investigate if the length of rectal stump influences the outcome of Hartmann's reversal surgery.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
201

participants targeted

Target at P75+ for all trials

Timeline
8mo left

Started Jun 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress59%
Jun 2025Dec 2026

First Submitted

Initial submission to the registry

February 21, 2025

Completed
14 days until next milestone

First Posted

Study publicly available on registry

March 7, 2025

Completed
3 months until next milestone

Study Start

First participant enrolled

June 1, 2025

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2026

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

March 7, 2025

Status Verified

February 1, 2025

Enrollment Period

1.1 years

First QC Date

February 21, 2025

Last Update Submit

March 6, 2025

Conditions

Keywords

colostomyhartmann

Outcome Measures

Primary Outcomes (1)

  • average post-operative hospital stay

    from the day of surgery to the the day of discharge from the hospital ( up to 10 days)

Study Arms (1)

patients undergoing Reversal Hartmann's procedure with open or laparoscopic technique

The study population includes all consecutive adult patients (≥18 years of age) underwent Hartmann's reversal procedure (open or laparoscopic procedure) in the participating centers

Procedure: Hartmann's reversal

Interventions

Colostomy reversal with laparoscopic technique after Hartmann's procedure ( procto-sigmoidectomy with end colostomy)

patients undergoing Reversal Hartmann's procedure with open or laparoscopic technique

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population includes all consecutive adult patients (≥18 years of age) underwent Hartmann's reversal procedure (open or laparoscopic procedure) in the participating centers. The decision to perform HR is based on the patients' preference and the attending surgeons' opinion and experience, after evaluating their clinical condition.

You may qualify if:

  • Patients of both sexes, ≥ 18 years old.
  • Patients who underwent Hartmann procedure for diverticulitis, intestinal ischemia or trauma
  • Patients who may face a one-year follow-up.
  • Patients fit for surgery.

You may not qualify if:

  • age \< 18.
  • patients that have undergone Hartmann's procedure for cancer and also post-Hartmann adjuvant radiotherapy or residual neoplastic disease.
  • immunodepression condition (patients undergoing chemo-radiotherapy and/or immunotherapy, patients undergoing immunosuppressive therapy for autoimmune diseases or transplants, cirrhotic class C and D patients, patients with chronic renal failure undergoing dialysis treatment.)
  • patients with missing data
  • Pregnancy or lactation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Central Study Contacts

Carla Vaccaro, Consultant Surgeon

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
6 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator Carla Vaccaro

Study Record Dates

First Submitted

February 21, 2025

First Posted

March 7, 2025

Study Start

June 1, 2025

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

March 7, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will share

Primary outcomes

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE